A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With Non-Muscle Invasive Bladder Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Non-muscle Invasive Bladder Cancer
Age: Between 18 Year(s) - 100 Year(s)
Gender: Male or Female

Other Inclusion Criteria:
1. Histologic confirmation of non-muscle invasive bladder cancer of the transitional cell carcinoma high-grade subtype
2. Currently eligible for intravesical BCG therapy
3. BCG-naive disease

You may not be eligible for this study if the following are true:

1. Prior BCG treatment or known hypersensitivity to BCG
2. Concurrent use of other investigational agents
3. History of or evidence of muscle-invasive, locally advanced, metastatic and/or extravesical bladder cancer or any other cancer within the past 5 years

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies